Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact on +44 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Testimonials
Within my time at Zenopa, I have found my Contractor Manager to offer the most fantastic support! The transition from my previous contract house was seamless and all the processes with Zenopa are very...
Jaz, 2012

Biogen Idec applies for new MS indication for Tysabri

16 January 2013 11:18 in Pharmaceutical Company Product News


Biogen Idec and its partner Elan Corporation have applied for approval of their multiple sclerosis (MS) therapy Tysabri in a new indication.

Applications have been submitted to the US Food and Drug Administration and European Medicines Agency requesting updates to the Tysabri label that would include first-line use for patients with certain relapsing forms of MS who have tested negative for antibodies to the JC virus.

These submissions are supported by risk stratification data and a risk algorithm that enables physicians and individuals living with MS to make informed decisions when considering Tysabri treatment.

Dr Alfred Sandrock, senior vice-president for development sciences and chief medical officer at Biogen Idec, said: "A first-line approval would allow people with MS access to a highly efficacious treatment earlier in the course of the disease, potentially leading to better outcomes."

To date, Tysabri has been approved for use in more than 65 countries and has been shown in clinical studies to reduce flare-ups and slow physical disability progression among those affected by the illness.ADNFCR-8000103-ID-801523012-ADNFCR

Other news stories from 16/01/2013

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd